Autoantibodies as biomarkers for ANCA-Associated vasculitides

Current Immunology Reviews

Volumn 7, Issue 4, 2011, Pages 407-414

  Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Granulomatosis with polyangiitis (GPA); Microscopic polyangiitis (MPA); MPO ANCA; PR3 ANCA

Indexed keywords

AUTOANTIBODY; BIOLOGICAL MARKER; NEUTROPHIL CYTOPLASMIC ANTIBODY;

ANCA ASSOCIATED VASCULITIS; ARTICLE; DISEASE ACTIVITY; DISEASE ASSOCIATION; HUMAN; MICROSCOPIC POLYANGIITIS; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL;

EID: 79953138060     PISSN: 15733955     EISSN: 1875631X     Source Type: Journal    
DOI: 10.2174/157339511797535072     Document Type: Article

References (52)

1. van der Woude FJ, Rasmussen N, Lobatto S, et al. Autoantibodies to neutrophils and monocytes: a new tool for diagnosis and a marker of disease activity in Wegener's Granulomatosis. Lancet 1985; 1(8426): 425-9.
2. Falk RJ, Jennette JC. Antineutrophil cytoplasmic autoantibodies with specificity for myeloperoxidase in patients with systemic vasculitis and idiopathic necrotizing and crescentic glomerulonephritis. N Engl J Med 1988; 318: 1651-7.
3. Goldschmeding R, van der Schoot CE, ten Bokkel Huinink D, et al. Wegener's Granulomatosis autoantibodies identify a novel diisopropylfluorophosphate-binding protein in the lysosomes of normal human neutrophils. J Clin Invest 1989; 84: 1577-87.
4. Ludemann J, Utecht B, Gross WL. Anti-neutrophil cytoplasm antibodies in Wegener's granulomatosis recognize an elastinolytic enzyme. J Exp Med 1990; 171: 357-62.
5. Kallenberg CGM, Mulder AHL, Cohen Tervaert JW. Anti-neutrophil cytoplasmic antibodies: a still growing class of autoantibodies in inflammatory disorders. Am J Med 1992; 93: 675-682.
6. Talor MV, Stone JH, Stebbing J, et al. Antibodies to selected minor target antigens in patients with anti-neutrophil cytoplasmic antibodies (ANCA). Clin Exp Immunol 2007;150: 42-8.
7. Peikert T, Finkielman JD, Hummel AM, et al. Functional characterization of antineutrophil cytoplasmic antibodies in patients with cocaine-induced midline destructive lesions. Arthritis Rheum. 2008; 58: 1546-51.
8. Kallenberg CG, Heeringa P, Stegeman CA. Mechanisms of Disease: pathogenesis and treatment of ANCA-associated vasculitides. Nat Clin Pract Rheumatol 2006; 2: 661-70.
9. Savige J, Gilles D, Benson E, et al. International Consensus Statement on testing and reporting of antineutrophil cytoplasmic antibodies (ANCA). Am J Clin Pathol 1999; 111: 507-13.
10. Savige J, Dimech W, Fritzler M, et al. Addendum to the international consensus statement on testing and reporting of antineutrophil cytoplasmic antibodies. Quality control guidelines, comments and recommendations for testing in other autoimmune diseases. Am J Clin Pathol 2003; 120: 312-8.
11. Van der Geld YM, Oost-Kort W, Limburg PC, Specks U, Kallenberg CGM. Recombinant proteinase 3 produced in different expression systems: recognition by anti-PR3 antibodies. J Immunol Methods 2000; 244: 117-31.
12. Finkielman JD, Merkel PA, Schroeder D, et al. Glycosylation of proteinase 3 (PR3) is not required for its reactivity with antineutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis. Clin Exp Rheumatol 2009; 27: S45-52.
13. Capizzi SA, Viss MA, Hummel AM, Fass DN, Specks U. Effects of carboxy-terminal modifications of proteinase 3 (PR3) on the recognition by PR3-ANCA. Kidney Int 2003; 63(2): 756-60.
14. Russell KA, Wiegert E, Schroeder DR, Homburger HA, Specks U. Detection of anti-neutrophil cytoplasmic antibodies under actual clinical testing conditions. Clin Immunol 2002; 103: 196-203.
15. Van der Geld YM, Limburg PC, Kallenberg CGM. Proteinase 3, Wegener's autoantigen: from gene to antigen. J Leukocyte Biol 2001; 69: 177-90.
16. Csernok E, Holle J, Hellmich B, et al. Evaluation of capture ELISA for detection of antineutrophil cytoplasmic antibodies directed against proteinase 3 in Wegener's granulomatosis: first results from a multicentre study. Rheumatology (Oxford) 2004; 43: 174-80.
17. Damoiseaux J, Dähnrich C, Rosemann A, et al. A novel enzyme-linked immunosorbent assay using a mixture of human native and recombinant proteinase-3 significantly improves the diagnostic potential for antineutrophil cytoplasmic antibody-associated vasculitis. Ann Rheum Dis 2009; 68: 228-33.
18. Lee AS, Finkielman JD, Peikert T, Hummel AM, Viss MA, Specks U. A novel capture-ELISA for detection of anti-neutrophil cytoplasmic antibodies (ANCA) based on c-myc peptide recognition in carboxy-terminally tagged recombinant neutrophil serine proteases. J Immunol Methods 2005; 307: 62-72.
19. Lee AS, Finkielman JD, Peikert T, et al. Agreement of anti-neutrophil cytoplasmic antibody measurements obtained from serum and plasma. Clin Exp Immunol 2006; 146: 15-20.
20. Hellmich B, Csernok E, Fredenhagen G, Gross W. A novel high sensitivity ELISA for detection of antineutrophil cytoplasm antibodies against proteinase-3. Clin Exp Rheumatol 2007; 25(1 suppl 44): S1-5.
21. Roggenbuck D, Buettner T, Hoffmann L, et al. High-sensitivity detection of autoantibodies against proteinase-3 by a novel third-generation enzyme-linked immunosorbent assay. Ann NY Acad Sci 2009; 1173: 41-6.
22. Stone JH, Talor M, Stebbing J, et al. Test characteristics of immunofluorescence and ELISA tests in 856 consecutive patients with possible ANCA-associated conditions. Arthritis Care Res 2000; 13: 424-34.
23. Hagen EC, Daha, MR, Hermans J, et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR project for ANCA assay standardization. Kidney Int 1998; 53: 743-53.
24. Watts RA, Jolliffe VA, Carruthers DM, Lockwood M, Scott DG. Effect of classification on the incidence of polyarteritis nodosa and microscopic polyangiitis. Arthritis Rheum 1996; 39: 1208-12.
25. Sinico RA, Di Toma L, Maggiore U, et al. Prevalence and clinical significance of antineutrophil cytoplasmic antibodies in Churg-Strauss syndrome. Arthritis Rheum 2005; 52: 2926-35.
26. Sable-Fourtassou R, Cohen P, Mahr A, et al. Antineutrophil cytoplasmic antibodies and the Churg-Strauss syndrome. Ann Intern Med 2005; 143: 632-8.
27. Kallenberg CGM. Churg-Strauss Syndrome: Just one disease entity? Arthritis Rheum 2005; 52: 89-93.
28. Franssen CFM, Stegeman CA, Kallenberg CGM, et al. Antiproteinase 3- and antimyeloperoxidase-associated vasculitis. Kidney Int 2000; 57: 2195-206.
29. Kain R, Exner M, Brandes R, Ziebermayr R, Cunningham D, Alderson CA et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nature Med 2008; 14: 1088-96.
30. Rarok AA, Limburg PC, Kallenberg CGM. Neutrophil-activating potential of antineutrophil cytoplasm autoantibodies. J Leuk Biol 2003; 74: 3-15.
31. Schreiber A, Rolle S, Peripelittchenko L, et al. Phosphoinositol 3-kinase-gamma mediates antineutrophil cytoplasmic autoantibody-induced glomerulonephritis. Kidney Int 2010; 77: 118-28.
32. Pankhurst T, Savage CO, Little MA. Review article: Leukocyte-endothelial dysregulation in systemic small vessel vasculitis. Nephrology (Carlton). 2009; 14: 3-10.
33. Xiao H, Heeringa P, Hu P, et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-63.
34. Little MA, Smyth CL, Yadav R, et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106: 2050-8.
35. Pfister H, Ollert M, Fröhlich LF, et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-8.
36. Van der Geld YM, Hellmark T, Selga D, et al. Rats and mice immunized with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007; 66: 1679-1682.
37. Schlieben DJ, Korbet SM, Kimura RE, Schwartz MM, Lewis EJ. Pulmonary-renal syndrome in a newborn with placental transmission of ANCAs. Am J Kidney Dis 2005; 45: 758-61.
38. Silva F, Specks U, Sethi S, Irazabal MV, Fervenza FC. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis 2009; 54: 542-5.
39. Terrier B, Saadoun D, Sène D, et al. Antimyeloperoxidase antibodies are a useful marker of disease activity in antineutrophil cytoplasmic antibody-associated vasculitides. Ann Rheum Dis 2009; 68: 1564-71.
40. Lin W, Chen M, Zhao MH. Follow-up of avidity and titer of anti-myeloperoxidase antibodies in sera from patients with primary ANCA-associated vasculitis. Autoimmunity 2009; 42: 198-202.
41. Boomsma MM, Stegeman CA, van der Leij MJ, Oost W, Hermans J, Kallenberg CGM, Limburg PC, Cohen Tervaert JW. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: a prospective study. Arthritis Rheum 2000; 43: 2025-33.
42. Kyndt X, Reumaux D, Bridoux F et al. Serial measurements of antineutrophil cytoplasmic autoantibodies in patients with systemic vasculitis. Am J Med 1999;106: 527-33.
43. Ara J, Mirapeix E, Rodriguez R, Saurina A, Darnell A. Relationship between ANCA and disease activity in small vessel vasculitis patients with anti-MPO ANCA. Nephrol Dial Transplant 1999; 14: 1667-72.
44. Cohen Tervaert JW, van der Woude FJ, Fauci AS, et al. Association between active Wegener's granulomatosis and anticytoplasmic antibodies. Arch Int Med 1989; 149: 2461-5.
45. Cohen Tervaert JW, Huitema MG, Hené RJ, et al. Prevention of relapses in Wegener's granulomatosis by treatment based on antineutrophil cytoplasmic antibody titre. Lancet 1990; 336: 709-711.
46. Birck R, Schmitt WH, Kaelsch IA, Woude van der FJ. Serial ANCA determinations for monitoring disease activity in patients with ANCA-associated vasculitis: systematic review. Am J Kidney Dis 2006; 47: 15-23.
47. Wegener Granulomatosis Etanercept Trial (WGET). N Engl J Med 2005; 352: 351-61.
48. Finkielman JD, Merkel PA, Schroeder D, et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med. 2007; 147: 611-619.
49. Finkielman JD, Lee AS, Hummel AM, et al. ANCA are detectable in nearly all patients with active severe Wegener's granulomatosis. Am J Med 2007; 120: 643. e9-14.
50. Stegeman CA, Cohen Tervaert JW, Sluiter WJ, et al. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener's Granulomatosis. Ann Intern Med 1994; 120: 12-17.
51. Sanders JS, Huitema MG, Kallenberg CG, Stegeman CA. 2006. Prediction of relapses in PR3-ANCA-associated vasculitis by assessing responses of ANCA titres to treatment. Rheumatology 2006; 45: 724-9.
52. Slot MC, Tervaert JW, Boomsma MM, Stegeman CA. Positive classic antineutrophil cytoplasmic antibody (C-ANCA) titer at switch to azathioprine therapy associated with relapse in proteinase 3-related vasculitis. Arthritis Rheum 2004; 51: 269-73.